Skip to main content
Journal of Oral and Maxillofacial Pathology : JOMFP logoLink to Journal of Oral and Maxillofacial Pathology : JOMFP
. 2019 Jan-Apr;23(1):19–27. doi: 10.4103/jomfp.JOMFP_13_19

Oral epithelial dysplasia: Classifications and clinical relevance in risk assessment of oral potentially malignant disorders

Kannan Ranganathan 1,, Loganathan Kavitha 1
PMCID: PMC6503768  PMID: 31110412

Abstract

After more than a decade, the World Health Organization (WHO) published the revised grading system for oral epithelial dysplasia in 2017. The revised classification has changes reflecting our evolution of understanding of the dysplastic process. Although the WHO 2017 three-tier grading system is the gold standard for histological diagnosis of oral potentially malignant disorders, it has certain limitations. Suggestions to overcome these limitations include the use of clinical determinants and molecular markers to supplement the grading system. It has also been suggested that a two-tier system may be more reproducible and clinically translatable for better management. These advances in the understanding of epithelial dysplasia are very important globally and for us in the Indian subcontinent, given the prevalence of habits (tobacco/areca nut) and burden of oral cancer in this part of the world. The following review traces the evolution of the grading system of dysplasia, its relevance and clinical utility.

Keywords: Cancer, epithelial, grading, histopathology, oral dysplasia, potentially malignant, precancer

INTRODUCTION

Oral cancer is the 11th most common cancer in the world, with an estimated 300,000 new cases and 145,000 deaths in 2012.[1,2] In India, 20/100,000 population are affected by oral cancer, which accounts for around 30% of all types of cancer.[3] Most cases of oral cancer are associated with habits (tobacco/areca nut) and are preceded by asymptomatic clinical lesions collectively referred to as oral potentially malignant disorder (OPMD).[4] OPMDs include leukoplakia, erythroplakia, reverse smoker's palate, erosive lichen planus, oral submucous fibrosis, lupus erythematosus and actinic keratosis.[5,6]

The worldwide prevalence rate of OPMDs ranges from 1% to 5%. Estimates provided by individual studies vary depending on the country, the population under investigation, the pattern of tobacco use and the clinical definition used for leukoplakia. One of the early epidemiological studies assessing the risk of OPMDs in India reported that 80% of oral cancers were preceded by OPMDs.[7] The global prevalence (1986 to 2002) of leukoplakia was estimated to be 1.49% to 2.60%.[8,9] The prevalence of erythroplakia among populations in India and Malaysia is estimated to be 0.02%.[10,11,12,13] Reported incidence rates of OPMDs in the Indian subcontinent have ranged between 0.6/1000 and 30.2/1000 with a regional variation in prevalence from 0.2% in Bihar state in the north to 4.9% in Andhra Pradesh in the east. This difference in the range is attributed to the prevalence and type of tobacco use.[14,15]

OPMD is a clinical diagnosis for which the histological diagnosis may be hyperplasia, hyperkeratosis, oral epithelial dysplasia (OED) or oral squamous cell carcinoma (OSCC). OED is characterized by cytological and architectural alterations reflecting the loss of normal maturation and stratification pattern of surface epithelium.[16,17]

This review aims to discuss the different classifications of OED, their limitations and relevance in determining the risk of malignant transformation. Understanding this relation between the clinical diagnosis of OPMD and histopathological diagnosis of OED is essential for early diagnosis and clinical management.

MALIGNANT TRANSFORMATION OF ORAL POTENTIALLY MALIGNANT DISORDER/ORAL EPITHELIAL DYSPLASIA TO ORAL SQUAMOUS CELL CARCINOMA

Oral leukoplakia is reported to carry up to 2-fold increased risk of developing oral cancer depending on the site and habits.[18] The MTR of leukoplakia varies from 1.4% to 7%.[19,20,21,22] A recent systematic review of the observational studies in OPMD reported an MTR of 0.13%–34% across 24 studies.[23] MTR of epithelial dysplasia ranges between 1.4% and 36% (Ho et al.: 1.4%–7.62% per year; Lumerman et al. 6.6%–36%).[16,21] The variation in rates between studies is attributed to differences in follow-up times, study group definition and selection and tobacco habits.[24]

Oral epithelial dysplasia – Terminology

The word dysplasia denotes abnormal growth.[25] The dysplastic alterations may revert to normal when the underlying inciting stimulus is removed. Dysplastic features in stratified squamous epithelium are characterized by cellular atypia and loss of normal maturation and stratification.[17] The World Health Organization (WHO) monograph on head and neck tumors (2005) uses the term “epithelial precursor lesions” and defines it as “altered epithelium with an increased likelihood for progression to squamous cell carcinoma.”[26]

Grading of oral epithelial dysplasia

The current evidence recognizes carcinogenesis of the epithelium as a multistep, progressive, cumulative process of genetic mutations which culminate in tumor formation, and ultimately invasion and metastasis.[27] In this model, simple epithelial hyperplasia progresses through mild OED, to more severe dysplastic changes with increasing genetic aberrations.[27,28] Grading of OED is used to assess the probability of malignant transformation. OED is observed in nearly all cases of erythroplakia and 1%–30% of oral leukoplakia cases at the time of diagnosis.[4,29]

The criteria used for diagnosing dysplasia include architectural changes (tissue changes) and cytological changes (individual cell changes/cytological atypia). The WHO three-tier grading of oral dysplasia is traditionally used by pathologists, in which OED is graded as mild, moderate and severe.

Classification systems for grading oral epithelial dysplasia

The main purpose of a classification and grading system is to promote uniform reporting and management. It should also serve as a means for assessing lesions in epidemiological studies. More than 20 classification systems have been proposed in the past two decades in an attempt to standardize OED grading systems. For any grading system to be clinically useful, it should be reproducible, and the histological assessment should reflect the malignant potential of the lesion. Many of these systems are based on the classification of precursor lesion in other sites, including Squamous Intraepithelial Neoplasia (SIN) of the cervix and the Ljubljana classification of larynx.[24,30] A comparison of important classification systems is given in Table 1 and discussed below:[24]

Table 1.

Comparison of Classification Systems for Histopathological Diagnosis of Oral Epithelial Dysplasia

WHO 1978 classification WHO 2005 classification WHO 2017 classification SIN 2005 Ljubljana classification 2003 SIL 1988 OIN/CIS (JSOP)system 2010 Binary system 2006
Mild dysplasia Squamoushyperplasia Mild dysplasia SIN 1 Low grade dysplasia Squamous cell (simple) hyperplasia Hyperplasia/keratosis Reactive atypical epithelium Low risk
Mild dysplasia Basal/parabasal cell hyperplasia* SIL I (low grade) Oral epithelial dysplasia
Moderate dysplasia Moderate dysplasia Moderate dysplasia SIN 2 High grade dysplasia Atypical hyperplasia** SIL II (high grade) OIN/CIS (JSOP)
Severe dysplasia Severe dysplasia Severe dysplasia SIN 3*** High risk
Carcinoma in situ Carcinoma in situ

*Basal/parabasal cell hyperplasia may histologically resemble mild dysplasia, but the former is conceptually benign lesion and the latter is the lower grade of precursor lesions, **lesions that represent ‘risky epithelium’ require close follow up and repeated histologic assessment to recognize any progression; approximate analogy to moderate and severe dysplasia, ***SIN 3 includes severe dysplasia and carcinoma in situ, classified as differentiated and basaloid types, with transitional variations between the two (several variations are not mentioned in the WHO classification definition). SIL: Squamous Intraepithelial Lesion, SIN: Squamous Intraepithelial Neoplasia, OIN: Oral Intraepithelial Neoplasia, CIS: Carcinoma in situ, JSOP: Japanese Society for Oral Pathology

Smith and Pindborg photographic methods (1969)

Smith and Pindborg described the first system for grading epithelial dysplasia of oral mucosa in the year 1969. They evaluated 13 histologic features, which were standardized by a set of photographs. Each feature was graded as absent, slight and marked. A grading of absent was scored as zero, whereas grading of slight or marked was allocated a score between 1 and 10 [Table 2].[31] The scores are added to give the epithelial atypia index (EAI) (0 to 75).[31]

Table 2.

Scoring in Smith and Pindborg grading system (depending on the epithelial atypia index)

Score Grade
0-10 No dysplasia
11-25 Mild dysplasia
26-45 Moderate dysplasia
Above 45 Severe dysplasia

EAI: Epithelial atypia index

In this system, the diagnosis of epithelial dysplasia is objective and semi-quantitative as the microscopic features are allocated a weighted score. However, the accuracy of weightage given to each of the histologic characteristics was subjective, and it was found to be difficult for routine use.

Ljubljana classification (2003)

The Ljubljana classification was first described by laryngeal pathologists Kambic and Lenart in 1971 for laryngeal hyperplastic lesions. Zerdoner in 2003 proposed the use of Ljubljana classification of laryngeal precancer for grading hyperplastic epithelial lesions of the oral cavity in four grades [Tables 1 and 3].[24,32]

Table 3.

Ljubljana grading system

Ljubljana grading system Treatment options
Simple hyperplasia Purely hyperplastic lesions that do not require close follow-up
Abnormal hyperplasia
Atypical hyperplasia or “risky” epithelium Mild degrees of atypia that require close follow-up to recognize any progression to severe atypia
Carcinoma in situ Severe atypia that require surgery or radiotherapy

The Ljubljana classification includes all histopathological changes that progress to squamous cell carcinoma each of which entails different treatment options. In this system, carcinoma in situ (CIS) is distinct from atypical hyperplasia, as these two entities differ in morphology and their progression to invasive carcinoma.[24]

Gale and Warnakulasuriya observe that the Ljubljana classification cannot categorize certain oral lesions such as oral submucous fibrosis and oral lichen planus, which have atrophic epithelium and are without significant atypia. Furthermore, this system is considered complex and time-consuming and needs to be validated for oral lesions.[24,26,30,33,34]

Squamous Intraepithelial Neoplasia/dysplasia (SIN/dysplasia) classification (2005)

SIN is a concept derived from cervical intraepithelial neoplasia. It has been extended with some modification of the WHO classification as “oral intraepithelial neoplasia.” It is also used for all sites of the upper aerodigestive tract (UADT). This system proposed

  • Unifying all the histological changes as “Oral Intra-epithelial Neoplasm”

  • Grading lesions as high grade and low grade.

However, it was argued that in UADT, surface maturation/keratinization can occur in the presence of dysplastic layers in the lower strata of epithelium, which is not a feature of cervical intraepithelial neoplasm. Hence, in UADT, a classification of SIN/dysplasia was introduced. It was a modification of 2005 WHO grading system [Table 1].[24,32,35] The important considerations of this classification are:

  1. Dysplasia is a spectrum

  2. One end of the spectrum is hyperplastic keratinizing SIN/dysplasia and the other end is atrophic SIN/dysplasia

  3. Hyperplastic keratinizing SIN/dysplasia is called keratinized dysplasia

  4. Atrophic SIN/dysplasia is similar to the WHO type dysplasia.

The hyperplastic keratinizing SIN/dysplasia and atrophic SIN/dysplasia clinically correspond to leukoplakia and erythroplakia, respectively. The disadvantage of this system was the overlap of features between the two ends of the spectrum leading to underdiagnosis of the grade. This system is largely based on subjective interpretation.[30] Crissman and Sakr emphasize that the lesions exhibiting keratinizing dysplasia have a high incidence of local relapse and a high progression rate to invasive SCC.[36,37,38,39,40]

Oral Intraepithelial Neoplasia/ Carcinoma in situ (Japanese Society for Oral Pathology), OIN/CIS (JSOP) system (2010)

In 2010, the Working Group of the Japan Society for Oral Tumours (WG–JSOT) proposed a new entity–oral intraepithelial neoplasia (OIN)–in the first edition of its “General Rules for Clinical and Pathological Studies on Oral Cancer.” The term OIN was introduced to avoid confusion with the WHO's term of CIS and to lay emphasis on the characteristics of oral SCC different from those of SCC of the uterine cervix. According to the Working Committee of the Japanese Society for Oral Pathology (JSOP), OIN/CIS system describes oral precursor lesions under three categories: reactive atypical epithelium, OED and OIN/CIS (JSOP) [Table 1].[24] Mucosal resection is recommended for the treatment of OIN/CIS (JSOP), whereas follow-up is recommended for OED in the OIN system.[24,41,42]

World Health Organization (WHO) classification systems

World Health Organization (WHO) 1978 classification

A collaborating reference center was established by the WHO in the year 1967, to characterize and define those lesions that should be considered as oral precancer and to determine their relative risk of becoming malignant.[17,33] In its report in 1978, the WHO defined and listed 12 characteristics of epithelial dysplasia and graded epithelial dysplasia as mild, moderate and severe and published the same in the “Histopathological typing of cancer and precancer of the oral mucosa,” in 1997, the characteristic histologic features were listed:

  1. Loss of polarity of basal cells

  2. Basaloid appearance in more than one layer of cells

  3. An increased nuclear-cytoplasmic ratio

  4. Drop-shaped rete pegs

  5. Irregular epithelial stratification

  6. Increased number of mitotic figures

  7. Mitotic figures in the superficial half of the epithelium

  8. Cellular polymorphism

  9. Nuclear hyperchromatism

  10. Enlarged nucleoli

  11. Reduction of cellular cohesion

  12. Keratinization of single cells or cell groups in the prickle cell layer (Kramer et al., 1978).

OED is graded as mild, moderate and severe based on whether dysplastic features were restricted to the lower third, middle third and the upper third of the epithelium, respectively [Table 1].[17,43,44]

World Health Organization (WHO) 2005 classification

The WHO 2005 classification recognizes five histopathological stages in epithelial precursor lesions: Squamous hyperplasia, mild dysplasia, moderate dysplasia, severe dysplasia and CIS. The criteria for diagnosing epithelial dysplasia are architectural and cytological/cellular changes [Table 4].[26]

Table 4.

World Health Organization (WHO) criteria for epithelial dysplasia (2005)

Architectural changes Cellular changes
Irregular epithelial stratification Abnormal variation in nuclear size (anisonucleosis)
Loss of polarity of basal cells Abnormal variation in nuclear shape (nuclear pleomorphism)
Basal cell hyperplasia* Abnormal variation in cell size (anisocytosis)
Drop-shaped rete ridges Abnormal variation in cell shape (cellular pleomorphism)
Increased number of mitotic figures Increased nuclear-cytoplasmic ratio
Abnormally superficial mitotic figures Increase in nuclear size*
Premature keratinization in single cells (dyskeratosis) Atypical mitotic figures
Keratin pearls within rete ridges Increased number and size of nucleoli
Hyperchromasia

*Present in 2005 WHO classification; has been removed in 2017 WHO classification. WHO: World Health Organization

Based on the architectural and cytological alterations, the epithelium is divided into “thirds,” and the lesions are classified into five categories [Table 1]:[5,26]

  1. Hyperplasia (Squamous hyperplasia): Lesions with an increase in cell number in the spinous layer and/or in the basal/parabasal cell layers. There is presence of regular stratification and no cellular atypia

  2. Mild dysplasia: Architectural disturbance present only in the lower third of the epithelium with cytological atypia

  3. Moderate dysplasia: The criteria postulate that architectural disturbance extending into the middle third of the epithelium, but the degree of cytological atypia may require upgrading it to “severe dysplasia”

  4. Severe dysplasia: Architectural disturbance observed in greater than two thirds of the epithelium, with cytological atypia

  5. Carcinoma in situ (CIS): Is a noninvasive carcinoma, classified as a precursor lesion of OSCC. CIS is characterized by full thickness or almost full thickness of epithelial architectural disturbance in the viable cell layers accompanied by pronounced cytological atypia.

World Health Organization (WHO) 2017 classification

In the recently published 2017 WHO grading system, features of “squamous hyperplasia (acanthosis and basal cell hyperplasia)” and “carcinoma in situ (CIS)” present in the 2005 WHO classification has been dropped from the OED grading [Table 1]. The term CIS is removed from the 2017 WHO classification and used synonymously with severe dysplasia. The cytological/cellular feature, “increase in nuclear size” in the 2005 WHO classification has also been dropped from 2017 WHO diagnostic criteria of OED. The architectural feature “loss of epithelial cell cohesion” has been included in 2017 WHO diagnostic criteria [Table 5].[45]

Table 5.

World Health Organization (WHO) criteria for epithelial dysplasia (2017)

Architectural changes Cellular changes
Irregular epithelial stratification Abnormal variation in nuclear size (anisonucleosis)
Loss of polarity of basal cells Abnormal variation in nuclear shape (nuclear pleomorphism)
Drop-shaped rete ridges Abnormal variation in cell size (anisocytosis)
Increased number of mitotic figures Abnormal variation in cell shape (cellular pleomorphism)
Abnormal superficial mitosis Increased nuclear-cytoplasmic ratio
Premature keratinization in single cells (dyskeratosis) Atypical mitotic figures
Keratin pearls within rete ridges Increased number and size of nucleoli
Loss of epithelial cell cohesion** Hyperchromasia

**Included in the 2017 WHO classification. WHO: World Health Organization

Binary system (2006)

Warnakulasuriya et al. in their review on OED classification system report that in the workshop conducted on issues related to OPMD in the United Kingdom, the WHO Collaborating Centre for Oral Cancer and Precancer (2005), the working group emphasized the need for two-tier classification – low risk (no / questionable / mild); high risk (moderate / severe) for better reproducibility and clinical utility. However, they added that further studies are needed before the two-tier system can be adopted [Table 1].[30,46]

The binary system for grading epithelial dysplasia categorizes OED into low risk and high risk for undergoing malignant transformation.[46] Kujan et al. in their study show that the binary system that uses four architectural and five cytological features had an increased inter-observer agreement (κ = 0.5) as compared to the WHO (κ = 0.22).[46] Nankivell et al. also contend that the binary system has a superior reproducibility, and a similar prognostic ability when compared to the three-tier WHO system.[47] They showed that the binary system with the use of four architectural features and four cytological features has a higher multi-observer kappa (κ = 0.59) compared with the WHO system (κ = 0.49).[47]

Although the three-tier grading systems (mild, moderate and severe) is widely used, the binary system complements the WHO classification systems, and it has merit as it helps clinicians to make critical clinical decisions particularly in cases with moderate dysplasia. It also facilitates a standardized approach to overcome some difficulty in subjectivity in reporting of epithelial dysplasia. However, the biological significance of this system needs to be validated in longitudinal studies to explore its value in the prediction of malignant transformation risk of OPMDs.

Oral epithelial dysplasia in the clinical context

The histopathologic assessment for the presence of OED is considered the current gold standard for predicting malignant transformation of OPMDs.[30] The presence of epithelial dysplasia is an indicator of the malignant potential of OPMDs, and the risk of these lesions to progress to carcinoma increases with the increasing grades of epithelial dysplasia.[48,49,50,51]

The efficacy and usefulness of histopathological grading of precursor lesions as an indicator of malignant transformation have long been debated in the literatures as malignant transformation of OPMDs can also occur in the absence of OED.[6,27,52,53,54] Furthermore, wide intra- and inter-observer variability in grading epithelial dysplasia raises the concern of reproducibility.[55,56,57,58]

Accurate clinical classification, supported by objective histopathological examination, will aid follow-up studies that aim to predict malignant transformation of OPMDs. In this context, prospective studies on OPMD/OED with longitudinal follow-up of patients are the need of the hour for clinical validation of the revised three-tier or binary system. Given the difficulty of conducting a longitudinal study, cases pooled from multiple sources are an alternative that needs to be considered.

Besides grading of OED, these studies also need to address clinical determinants and molecular diagnostic aids, which are briefly discussed below.

Clinical determinants of malignant transformation

The risk factors to predict the malignant transformation of OPMDs remains challenging.[59] van der Waal I[5,60] and Lee JJ[61] reported major risk factors for the malignant transformation include

  • Female gender

  • Long duration of leukoplakia

  • Leukoplakia in non-smokers (idiopathic leukoplakia)

  • Site predilection for tongue and/or floor of the mouth

  • Size ≥200 mm2

  • Non-homogenous type.

Gender predilection

In India, MTRs of leukoplakia are greater in men than in women, possibly because of the association with chewing tobacco and smoking habits[21,62,63] whereas in Europe and other western countries, it is greater in women than men.[4,5,15,64,65,66]

Duration

Cancers from dysplastic lesions usually develop over a period of 2–5 years, but can occur much later.[50,67,68] Time frame for this process varies, but it is thought to be a relatively slow process, with malignant transformation occurring over a period of few years.[69]

Smokers versus non-smokers

Lesions in non-smokers are 7.1 times more likely to undergo malignant transformation compared to heavy smokers.[16,19,20,64]

Anatomical location

The floor of the mouth and/or on the lateral tongue has a high risk for malignant transformation.[21,64,70,71,72]

Homogenous versus non-homogenous leukoplakia

Reibel and Holmstrup considered non-homogenous appearance as an important marker for malignant transformation.[73] Although the most common clinical type of leukoplakia is homogenous, a higher malignant transformation (13.1%) occurs among the non-homogenous clinical types.[23,64,73,74] Speckled and erosive leukoplakia have the highest MTR.[66,75] Homogenous, thick leukoplakia undergoes malignant transformation in 1%–7% of cases. Once the surface becomes granular or verruciform, the malignant transformation potential becomes 4%–15%. Erythroleukoplakia carries an average transformation potential of 28%, but the rates vary from 18% to 47% in different studies.[68]

Other clinical determinants

Large lesions (≥200 mm2),[64,76,77] multifocal or multiple leukoplakia,[62,63] and proliferative verrucous leukoplakia[20,77,78,79,80] are also associated with increased risk of malignant transformation. Advancing age is also shown be an important determinant of malignant transformation.[19,75,78,81,82] The presence of aneuploidy has been found to signify a high risk of malignant transformation in leukoplakia.[83,84,85,86]

Other prognostic indicators

It has been suggested that the use of molecular markers along with clinical and histological grading can better predict disease progression. Alterations and mutations in the genetic content of oral epithelium are an integral part of “premalignancy.”[87,88] Many genes and signaling pathways have been shown to be involved in the development of OSCC. Molecular markers that correlate OED with malignant transformation[89] include:

  1. Overexpression of EGFR,[90] c-Jun,[91] Ki67/Mcm2,[92] Cyclins D and E,[93] p53,[94,95,96] p63,[97] survivin, MMP-9,[98] TGF alpha,[99,90] COX-1 and-2[100,101,102]

  2. Amplification of Cyclin D1[103,104]

  3. Loss of c-erbB2,[105] pRB[106]

  4. Upregulation of telomerase (human telomerase reverse transcriptase; hTERT)[107,108,109]

  5. Aneuploidy[84]

  6. Loss of heterozygosity (Chromosome loci 3p, 8p, 9p, 4q, 11q, 13q, 17p)[110,111,112]

  7. Cytokeratins (CK 1, CK 8 and CK 18)[113,114]

  8. High-risk Human papillomavirus, p16.[115]

Progress in molecular oncology has significantly advanced the knowledge on tumorigenesis; however, the clinical utility of these genetic markers in OPMD/OED need to be defined.

CONCLUSION

Oral squamous cell carcinoma is often diagnosed in the late stages of the disease. Delayed diagnosis precludes successful treatment and favorable outcomes. Oral potentially malignant disorders are associated with the variable rate of malignant progression, with the finding of oral epithelial dysplasia on tissue biopsy remaining the gold standard in guiding management.

Long-term prospective studies are imperative to understand the natural history of oral potentially malignant disorders and oral squamous cell carcinoma, to facilitate diagnosis of at an early stage and render appropriate treatment, thereby reducing the morbidity and the mortality associated with advanced stage of oral cancer.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

  • 1.Sankaranarayanan R, Ramadas K, Amarasinghe H, Subramanian S, Johnson N. Oral cancer: Prevention, early detection, and treatment. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities. 3rd ed. Ch. 5. Vol. 3. Washington, (DC): The International Bank for Reconstruction and Development/The World Bank; 2015. [PubMed] [Google Scholar]
  • 2.Kalavrezos N, Scully C. Mouth cancer for clinicians. Part 2: Epidemiology. Dent Update. 2015;42:354–6. doi: 10.12968/denu.2015.42.4.354. 358-9. [DOI] [PubMed] [Google Scholar]
  • 3.Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, et al. Effect of screening on oral cancer mortality in Kerala, India: A cluster-randomised controlled trial. Lancet. 2005;365:1927–33. doi: 10.1016/S0140-6736(05)66658-5. [DOI] [PubMed] [Google Scholar]
  • 4.Reibel J. Prognosis of oral pre-malignant lesions: Significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14:47–62. doi: 10.1177/154411130301400105. [DOI] [PubMed] [Google Scholar]
  • 5.van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45:317–23. doi: 10.1016/j.oraloncology.2008.05.016. [DOI] [PubMed] [Google Scholar]
  • 6.Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575–80. doi: 10.1111/j.1600-0714.2007.00582.x. [DOI] [PubMed] [Google Scholar]
  • 7.Gupta PC, Bhonsle RB, Murti PR, Daftary DK, Mehta FS, Pindborg JJ, et al. An epidemiologic assessment of cancer risk in oral precancerous lesions in India with special reference to nodular leukoplakia. Cancer. 1989;63:2247–52. doi: 10.1002/1097-0142(19890601)63:11<2247::aid-cncr2820631132>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  • 8.Petti S. Pooled estimate of world leukoplakia prevalence: A systematic review. Oral Oncol. 2003;39:770–80. doi: 10.1016/s1368-8375(03)00102-7. [DOI] [PubMed] [Google Scholar]
  • 9.Downer MC, Petti S. Leukoplakia prevalence estimate lower than expected. Evid Based Dent. 2005;6:12. doi: 10.1038/sj.ebd.6400306. [DOI] [PubMed] [Google Scholar]
  • 10.Dionne KR, Warnakulasuriya S, Zain RB, Cheong SC. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory. Int J Cancer. 2015;136:503–15. doi: 10.1002/ijc.28754. [DOI] [PubMed] [Google Scholar]
  • 11.Malaysia: Dental Division Ministry of Health Malaysia; 1978. Dental Division Ministry of Health Malaysia, editor. Dental Epidemiological Survey of Adults in Peninsular Malaysia. 1974/75 ed; pp. 98–9. [Google Scholar]
  • 12.Mehta FS, Pindborg JJ, Hamner JE., 3rd . Bombay: Basic Dental Research Unit, Tata Institute of Fundamental Research; 1971. Report on Oral Cancer and Precancerous Conditions in Indian Rural Populations, 1966–1969. [Google Scholar]
  • 13.Zain RB, Ikeda N, Razak IA, Axéll T, Majid ZA, Gupta PC, et al. Anational epidemiological survey of oral mucosal lesions in Malaysia. Community Dent Oral Epidemiol. 1997;25:377–83. doi: 10.1111/j.1600-0528.1997.tb00959.x. [DOI] [PubMed] [Google Scholar]
  • 14.Baric JM, Alman JE, Feldman RS, Chauncey HH. Influence of cigarette, pipe, and cigar smoking, removable partial dentures, and age on oral leukoplakia. Oral Surg Oral Med Oral Pathol. 1982;54:424–9. doi: 10.1016/0030-4220(82)90389-9. [DOI] [PubMed] [Google Scholar]
  • 15.Smith LW, Bhargava K, Mani NJ, Malaowalla AM, Silverman S., Jr Oral cancer and precancerous lesions in 57,518 industrial workers of Gujarat, India. Indian J Cancer. 1975;12:118–23. [PubMed] [Google Scholar]
  • 16.Ho PS, Chen PL, Warnakulasuriya S, Shieh TY, Chen YK, Huang IY, et al. Malignant transformation of oral potentially malignant disorders in males: A retrospective cohort study. BMC Cancer. 2009;9:260. doi: 10.1186/1471-2407-9-260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Berlin: Springer-Verlag; 1997. World Health Organization: Histological Typing of Cancer and Precancer of the Oral Mucosa. [Google Scholar]
  • 18.van der Waal I, Schepman KP, van der Meij EH, Smeele LE. Oral leukoplakia: A clinicopathological review. Oral Oncol. 1997;33:291–301. doi: 10.1016/s1368-8375(97)00002-x. [DOI] [PubMed] [Google Scholar]
  • 19.Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: A follow-up study of a hospital-based population of 166 patients with oral leukoplakia from the Netherlands. Oral Oncol. 1998;34:270–5. [PubMed] [Google Scholar]
  • 20.Silverman S, Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984;53:563–8. doi: 10.1002/1097-0142(19840201)53:3<563::aid-cncr2820530332>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  • 21.Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79:321–9. doi: 10.1016/s1079-2104(05)80226-4. [DOI] [PubMed] [Google Scholar]
  • 22.Hsue SS, Wang WC, Chen CH, Lin CC, Chen YK, Lin LM, et al. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: A follow-up study based in a Taiwanese hospital. J Oral Pathol Med. 2007;36:25–9. doi: 10.1111/j.1600-0714.2006.00491.x. [DOI] [PubMed] [Google Scholar]
  • 23.Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: A systematic review of observational studies. J Oral Pathol Med. 2016;45:155–66. doi: 10.1111/jop.12339. [DOI] [PubMed] [Google Scholar]
  • 24.Izumo T. Oral premalignant lesions: From the pathological viewpoint. Int J Clin Oncol. 2011;16:15–26. doi: 10.1007/s10147-010-0169-z. [DOI] [PubMed] [Google Scholar]
  • 25.Rastogi V, Puri N, Mishra S, Arora S, Kaur G, Yadav L. An insight to oral epithelial dysplasia. Int J Head Neck Surg. 2013;4:74–82. [Google Scholar]
  • 26.Barnes L, Eveson JW, Reichart P, Sidransky S. Lyon, France: International Agency for Research on Cancer Press; 2005. World Health Organisation Classification of Tumours. Pathology and Genetics. Head and Neck Tumours. [Google Scholar]
  • 27.Gale N, Michaels L, Luzar B, Poljak M, Zidar N, Fischinger J, et al. Current review on squamous intraepithelial lesions of the larynx. Histopathology. 2009;54:639–56. doi: 10.1111/j.1365-2559.2008.03111.x. [DOI] [PubMed] [Google Scholar]
  • 28.Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res. 1996;56:2488–92. [PubMed] [Google Scholar]
  • 29.Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer. 1975;36:1021–8. doi: 10.1002/1097-0142(197509)36:3<1021::aid-cncr2820360327>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  • 30.Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: Predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008;37:127–33. doi: 10.1111/j.1600-0714.2007.00584.x. [DOI] [PubMed] [Google Scholar]
  • 31.Smith C, Pindborg JJ. Copenhagen: C. Hamburgers Bogtrykkeri; 1969. Histologic Grading of Oral epithelial atypia by the use of Photographic Standards. [Google Scholar]
  • 32.Zerdoner D. The Ljubljana classification – Its application to grading oral epithelial hyperplasia. J Craniomaxillofac Surg. 2003;31:75–9. doi: 10.1016/s1010-5182(02)00186-5. [DOI] [PubMed] [Google Scholar]
  • 33.Sadiq H, Gupta P, Singh N, Thakar SS, Prabhakar I, Thakral J. Various grading systems of oral epithelial dysplasia: A review. Int J Adv Health Sci. 2015;1:20–6. [Google Scholar]
  • 34.Gale N, Zidar N, Fischinger J, Kambic V. Clinical applicability of the Ljubljana classification of epithelial hyperplastic laryngeal lesions. Clin Otolaryngol Allied Sci. 2000;25:227–32. doi: 10.1046/j.1365-2273.2000.00352.x. [DOI] [PubMed] [Google Scholar]
  • 35.Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1967;10:748–84. [Google Scholar]
  • 36.Crissman JD, Sakr WA. Squamous intraepithelial neoplasia of upper aerodigestive tract. In: Gnepp DR, editor. Diagnostic Surgical Pathology of the Head and Neck. Philadelphia: Saunders; 2001. pp. 1–17. [Google Scholar]
  • 37.Sakr WA, Gale N, Gnepp DR, Crissman JD. Squamous intraepithelial neoplasia of the upper aerodigestive tract. In: Gnepp DR, editor. Diagnostic Surgical Pathology of the Head and Neck. 2nd ed. Philadelphia: Saunders; 2009. pp. 1–44. [Google Scholar]
  • 38.Fleskens S, Slootweg P. Grading systems in head and neck dysplasia: Their prognostic value, weakness and utility. Head Neck Oncol. 2009;1:1–8. doi: 10.1186/1758-3284-1-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gale N, Pilch BZ, Sidransky D, Westra W, Califano J. Tumours of the hypopharynx, larynx and trachea (Epithelial precursor lesions) In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization Classification of Tumours. Pathology & Genetics. Head and Neck Tumours. Lyon: International Agency for Research on Cancer Press; 2005. pp. 140–3. [Google Scholar]
  • 40.Gale N, Pilch BZ, Sidransky D, El-Naggar AK, Westra W, Califano J, et al. Tumours of the oral cavity and oropharynx (Epithelial precursor lesions) In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization Classification of Tumours. Pathology & Genetics. Head and Neck Tumours. Lyon: International Agency for Research on Cancer Press; 2005. pp. 177–9. [Google Scholar]
  • 41.Tokyo: Sunashobo Publishing; 2007. Working Committee of New Histopathological Criteria for Borderline Malignancies of the Oral Mucosa. Japanese Society for Oral Pathology Oral CIS (JSOP) Catalogue: Histopathological Variations. [Google Scholar]
  • 42.1st ed. Tokyo: Kanehara; 2010. Japan Society for Oral Tumors. General Rules for Clinical and Pathological Studies on Oral Cancer (in Japanese) [Google Scholar]
  • 43.Geetha KM, Leeky M, Narayan TV, Sadhana S, Saleha J. Grading of oral epithelial dysplasia: Points to ponder. J Oral Maxillofac Pathol. 2015;19:198–204. doi: 10.4103/0973-029X.164533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rajendran R, Sivapathasundharam B. 7th ed. India: Elsevier; 2012. Shafer's Textbook of Oral Pathology; p. 88. [Google Scholar]
  • 45.El-Naggar AK, Chan JK, Grandis JR, Takata T, Slootweg PJ. 4th ed. Vol. 9. International Agency for Research on Cancer (IARC) press; 2017. WHO Classification of Head and Neck Tumors. WHO/IARC Classification of Tumours. [Google Scholar]
  • 46.Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P, et al. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol. 2006;42:987–93. doi: 10.1016/j.oraloncology.2005.12.014. [DOI] [PubMed] [Google Scholar]
  • 47.Nankivell P, Williams H, Matthews P, Suortamo S, Snead D, McConkey C, et al. The binary oral dysplasia grading system: Validity testing and suggested improvement. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:87–94. doi: 10.1016/j.oooo.2012.10.015. [DOI] [PubMed] [Google Scholar]
  • 48.Liu W, Bao ZX, Shi LJ, Tang GY, Zhou ZT. Malignant transformation of oral epithelial dysplasia: Clinicopathological risk factors and outcome analysis in a retrospective cohort of 138 cases. Histopathology. 2011;59:733–40. doi: 10.1111/j.1365-2559.2011.03938.x. [DOI] [PubMed] [Google Scholar]
  • 49.MacDonald DG, Saka SM. Structural indicators of the high risk lesion. In: Johnson NE, editor. Risk Markers for Oral Diseases. Oral Cancer: Detection of Patients and Lesions at Risk. Vol. 2. Cambridge: Cambridge University Press; 1991. pp. 165–87. [Google Scholar]
  • 50.van der Waal I, Axéll T. Oral leukoplakia: A proposal for uniform reporting. Oral Oncol. 2002;38:521–6. doi: 10.1016/s1368-8375(01)00125-7. [DOI] [PubMed] [Google Scholar]
  • 51.Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck. 2009;31:1600–9. doi: 10.1002/hed.21131. [DOI] [PubMed] [Google Scholar]
  • 52.Tilakaratne WM, Sherriff M, Morgan PR, Odell EW. Grading oral epithelial dysplasia: Analysis of individual features. J Oral Pathol Med. 2011;40:533–40. doi: 10.1111/j.1600-0714.2011.01033.x. [DOI] [PubMed] [Google Scholar]
  • 53.Speight PM. Update on oral epithelial dysplasia and progression to cancer. Head Neck Pathol. 2007;1:61–6. doi: 10.1007/s12105-007-0014-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Dost F, Lê Cao K, Ford PJ, Ades C, Farah CS. Malignant transformation of oral epithelial dysplasia: A real-world evaluation of histopathologic grading. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:343–52. doi: 10.1016/j.oooo.2013.09.017. [DOI] [PubMed] [Google Scholar]
  • 55.Pindborg JJ, Reibel J, Holmstrup P. Subjectivity in evaluating oral epithelial dysplasia, carcinoma in situ and initial carcinoma. J Oral Pathol. 1985;14:698–708. doi: 10.1111/j.1600-0714.1985.tb00549.x. [DOI] [PubMed] [Google Scholar]
  • 56.Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;80:188–91. doi: 10.1016/s1079-2104(05)80201-x. [DOI] [PubMed] [Google Scholar]
  • 57.Karabulut A, Reibel J, Therkildsen MH, Praetorius F, Nielsen HW, Dabelsteen E, et al. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med. 1995;24:198–200. doi: 10.1111/j.1600-0714.1995.tb01166.x. [DOI] [PubMed] [Google Scholar]
  • 58.Fischer DJ, Epstein JB, Morton TH, Schwartz SM. Interobserver reliability in the histopathologic diagnosis of oral pre-malignant and malignant lesions. J Oral Pathol Med. 2004;33:65–70. doi: 10.1111/j.1600-0714.2004.0037n.x. [DOI] [PubMed] [Google Scholar]
  • 59.Scully C. Challenges in predicting which oral mucosal potentially malignant disease will progress to neoplasia. Oral Dis. 2014;20:1–5. doi: 10.1111/odi.12208. [DOI] [PubMed] [Google Scholar]
  • 60.van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncol. 2010;46:423–5. doi: 10.1016/j.oraloncology.2010.02.016. [DOI] [PubMed] [Google Scholar]
  • 61.Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res. 2000;6:1702–10. [PubMed] [Google Scholar]
  • 62.Hamadah O, Goodson ML, Thomson PJ. Clinicopathological behaviour of multiple oral dysplastic lesions compared with that of single lesions. Br J Oral Maxillofac Surg. 2010;48:503–6. doi: 10.1016/j.bjoms.2009.08.027. [DOI] [PubMed] [Google Scholar]
  • 63.Yang SW, Tsai CN, Lee YS, Chen TA. Treatment outcome of dysplastic oral leukoplakia with carbon dioxide laser – Emphasis on the factors affecting recurrence. J Oral Maxillofac Surg. 2011;69:e78–87. doi: 10.1016/j.joms.2010.11.029. [DOI] [PubMed] [Google Scholar]
  • 64.Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: An overview of the literature. J Oral Pathol Med. 2008;37:1–10. doi: 10.1111/j.1600-0714.2007.00579.x. [DOI] [PubMed] [Google Scholar]
  • 65.Ray JG, Ranganathan K, Chattopadhyay A. Malignant transformation of oral submucous fibrosis: Overview of histopathological aspects. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:200–9. doi: 10.1016/j.oooo.2015.11.024. [DOI] [PubMed] [Google Scholar]
  • 66.Silverman S, Bhargava K, Smith LW, Malaowalla AM. Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer. 1976;38:1790–5. doi: 10.1002/1097-0142(197610)38:4<1790::aid-cncr2820380456>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  • 67.Jerjes W, Upile T, Hamdoon Z, Al-Khawalde M, Morcos M, Mosse CA, et al. CO2 laser of oral dysplasia: Clinicopathological features of recurrence and malignant transformation. Lasers Med Sci. 2012;27:169–79. doi: 10.1007/s10103-011-0916-z. [DOI] [PubMed] [Google Scholar]
  • 68.Neville B, Damm D, Allen C, Bouquot J. 2nd ed. Philadelphia: W.B. Saunders; 2002. Oral and Maxillofacial Pathology. [Google Scholar]
  • 69.Bouquot JE, Speight PM, Farthing PM. Epithelial dysplasia of the oral mucosa – Diagnostic problems and prognostic features. Curr Diagn Pathol. 2006;12:11–21. [Google Scholar]
  • 70.Kramer IR, Lucas RB, el-Labban N, Lister L. The use of discriminant analysis for examining the histological feathers of oral keratoses and lichen planus. Br J Cancer. 1970;24:673–83. doi: 10.1038/bjc.1970.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer. 1975;36:1386–92. doi: 10.1002/1097-0142(197510)36:4<1386::aid-cncr2820360430>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  • 72.Warnakulasuriya S. SCC and precursor lesions: Prevention. Periodontology. 2011;57:38–50. doi: 10.1111/j.1600-0757.2011.00395.x. [DOI] [PubMed] [Google Scholar]
  • 73.Reibel J, Holmstrup P. Premalignant disorders and cancer of the oral mucosa. Ugeskr Laeger. 2010;172:3040–2. [PubMed] [Google Scholar]
  • 74.Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006;42:461–74. doi: 10.1016/j.oraloncology.2005.08.011. [DOI] [PubMed] [Google Scholar]
  • 75.Chiesa F, Sala L, Costa L, Moglia D, Mauri M, Podrecca S, et al. Excision of oral leukoplakias by CO2 laser on an out-patient basis: A useful procedure for prevention and early detection of oral carcinomas. Tumori. 1986;72:307–12. doi: 10.1177/030089168607200312. [DOI] [PubMed] [Google Scholar]
  • 76.Cowan CG, Gregg TA, Napier SS, McKenna SM, Kee F. Potentially malignant oral lesions in Northern Ireland: A 20-year population-based perspective of malignant transformation. Oral Dis. 2001;7:18–24. [PubMed] [Google Scholar]
  • 77.Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: A leukoplakia cohort in Taiwan. Br J Cancer. 2000;82:1871–4. doi: 10.1054/bjoc.2000.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Hansen LS, Olson JA, Silverman S., Jr Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Oral Med Oral Pathol. 1985;60:285–98. doi: 10.1016/0030-4220(85)90313-5. [DOI] [PubMed] [Google Scholar]
  • 79.Cabay RJ, Morton TH, Jr, Epstein JB. Proliferative verrucous leukoplakia and its progression to oral carcinoma: A review of the literature. J Oral Pathol Med. 2007;36:255–61. doi: 10.1111/j.1600-0714.2007.00506.x. [DOI] [PubMed] [Google Scholar]
  • 80.Holmstrup P, Dabelsteen E. Oral leukoplakia-to treat or not to treat. Oral Dis. 2016;22:494–7. doi: 10.1111/odi.12443. [DOI] [PubMed] [Google Scholar]
  • 81.Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol. 1980;8:283–333. doi: 10.1111/j.1600-0528.1980.tb01302.x. [DOI] [PubMed] [Google Scholar]
  • 82.Bánóczy J. Follow-up studies in oral leukoplakia. J Maxillofac Surg. 1977;5:69–75. doi: 10.1016/s0301-0503(77)80079-9. [DOI] [PubMed] [Google Scholar]
  • 83.Bremmer JF, Brakenhoff RH, Broeckaert MA, Beliën JA, Leemans CR, Bloemena E, et al. Prognostic value of DNA ploidy status in patients with oral leukoplakia. Oral Oncol. 2011;47:956–60. doi: 10.1016/j.oraloncology.2011.07.025. [DOI] [PubMed] [Google Scholar]
  • 84.Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol. 2009;45:468–73. doi: 10.1016/j.oraloncology.2008.07.006. [DOI] [PubMed] [Google Scholar]
  • 85.Bradley G, Odell EW, Raphael S, Ho J, Le LW, Benchimol S, et al. Abnormal DNA content in oral epithelial dysplasia is associated with increased risk of progression to carcinoma. Br J Cancer. 2010;103:1432–42. doi: 10.1038/sj.bjc.6605905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Sperandio M, Brown AL, Lock C, Morgan PR, Coupland VH, Madden PB, et al. Predictive value of dysplasia grading and DNA ploidy in malignant transformation of oral potentially malignant disorders. Cancer Prev Res (Phila) 2013;6:822–31. doi: 10.1158/1940-6207.CAPR-13-0001. [DOI] [PubMed] [Google Scholar]
  • 87.Scully C, Sudbø J, Speight PM. Progress in determining the malignant potential of oral lesions. J Oral Pathol Med. 2003;32:251–6. doi: 10.1034/j.1600-0714.2003.00108.x. [DOI] [PubMed] [Google Scholar]
  • 88.Lingen MW, Pinto A, Mendes RA, Franchini R, Czerninski R, Tilakaratne WM, et al. Genetics/epigenetics of oral premalignancy: Current status and future research. Oral Dis. 2011;17(Suppl 1):7–22. doi: 10.1111/j.1601-0825.2011.01789.x. [DOI] [PubMed] [Google Scholar]
  • 89.Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S. Molecular markers in oral epithelial dysplasia: Review. J Oral Pathol Med. 2009;38:737–52. doi: 10.1111/j.1600-0714.2009.00804.x. [DOI] [PubMed] [Google Scholar]
  • 90.Srinivasan M, Jewell SD. Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oncology. 2001;61:284–92. doi: 10.1159/000055335. [DOI] [PubMed] [Google Scholar]
  • 91.Turatti E, da Costa Neves A, de Magalhães MH, de Sousa SO. Assessment of c-jun, c-fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci. 2005;47:71–6. doi: 10.2334/josnusd.47.71. [DOI] [PubMed] [Google Scholar]
  • 92.Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer. 2009;100:1128–34. doi: 10.1038/sj.bjc.6604967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Oliver RJ, MacDonald DG. G1 cyclins in oral epithelial dysplasia. J Oral Pathol Med. 2001;30:80–6. doi: 10.1034/j.1600-0714.2001.300203.x. [DOI] [PubMed] [Google Scholar]
  • 94.Murti PR, Warnakulasuriya KA, Johnson NW, Bhonsle RB, Gupta PC, Daftary DK, et al. P53 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med. 1998;27:191–6. doi: 10.1111/j.1600-0714.1998.tb01940.x. [DOI] [PubMed] [Google Scholar]
  • 95.Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM, et al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol. 1998;184:360–8. doi: 10.1002/(SICI)1096-9896(199804)184:4<360::AID-PATH1263>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 96.Kövesi G, Szende B. Prognostic value of cyclin D1, p27, and p63 in oral leukoplakia. J Oral Pathol Med. 2006;35:274–7. doi: 10.1111/j.1600-0714.2006.00396.x. [DOI] [PubMed] [Google Scholar]
  • 97.Varun BR, Ranganathan K, Rao UK, Joshua E. Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral submucous fibrosis. J Investig Clin Dent. 2014;5:214–9. doi: 10.1111/jicd.12038. [DOI] [PubMed] [Google Scholar]
  • 98.Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: A systematic review. Oral Oncol. 2009;45:647–53. doi: 10.1016/j.oraloncology.2009.02.006. [DOI] [PubMed] [Google Scholar]
  • 99.Kannan R, Bijur GN, Mallery SR, Beck FM, Sabourin CL, Jewell SD, et al. Transforming growth factor-alpha overexpression in proliferative verrucous leukoplakia and oral squamous cell carcinoma: An immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:69–74. doi: 10.1016/s1079-2104(96)80379-9. [DOI] [PubMed] [Google Scholar]
  • 100.Shibata M, Kodani I, Osaki M, Araki K, Adachi H, Ryoke K, et al. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol. 2005;41:304–12. doi: 10.1016/j.oraloncology.2004.09.009. [DOI] [PubMed] [Google Scholar]
  • 101.Sun XJ, Ma J, Zhang H, Wang XK, Li JH. The expressions of cyclooxygenase-2 (Cox-2), VEGF in oral squamous cell carcinoma and precancerous lesions and their significances. Shanghai Kou Qiang Yi Xue. 2005;14:173–6. [PubMed] [Google Scholar]
  • 102.Zhang S, Du Y, Tao J, Wu Y, Chen N. Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas. ORL J Otorhinolaryngol Relat Spec. 2008;70:242–8. doi: 10.1159/000130872. [DOI] [PubMed] [Google Scholar]
  • 103.Izzo JG, Papadimitrakopoulou VA, Li XQ, Ibarguen H, Lee JS, Ro JY, et al. Dysregulated cyclin D1 expression early in head and neck tumorigenesis:In vivo evidence for an association with subsequent gene amplification. Oncogene. 1998;17:2313–22. doi: 10.1038/sj.onc.1202153. [DOI] [PubMed] [Google Scholar]
  • 104.Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, et al. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) 2009;2:14–21. doi: 10.1158/1940-6207.CAPR-08-0111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Kilpi A, Rich AM, Konttinen YT, Reade PC. Expression of c-erbB-2 protein in keratinocytes of oral mucosal lichen planus and subsequent squamous cell carcinoma. Eur J Oral Sci. 1996;104:278–84. doi: 10.1111/j.1600-0722.1996.tb00078.x. [DOI] [PubMed] [Google Scholar]
  • 106.Soni S, Kaur J, Kumar A, Chakravarti N, Mathur M, Bahadur S, et al. Alterations of Rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology. 2005;68:314–25. doi: 10.1159/000086970. [DOI] [PubMed] [Google Scholar]
  • 107.Palani J, Lakshminarayanan V, Kannan R. Immunohistochemical detection of human telomerase reverse transcriptase in oral cancer and pre-cancer. Indian J Dent Res. 2011;22:362. doi: 10.4103/0970-9290.84281. [DOI] [PubMed] [Google Scholar]
  • 108.Mutirangura A, Supiyaphun P, Trirekapan S, Sriuranpong V, Sakuntabhai A, Yenrudi S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res. 1996;56:3530–3. [PubMed] [Google Scholar]
  • 109.Kannan S, Tahara H, Yokozaki H, Mathew B, Nalinakumari KR, Nair MK, et al. Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epidemiol Biomarkers Prev. 1997;6:413–20. [PubMed] [Google Scholar]
  • 110.Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357–62. [PubMed] [Google Scholar]
  • 111.Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996;2:682–5. doi: 10.1038/nm0696-682. [DOI] [PubMed] [Google Scholar]
  • 112.Partridge M, Emilion G, Falworth M, A’Hern R, Phillips E, Pateromichelakis S, et al. Patient-specific mutation databases for oral cancer. Int J Cancer. 1999;84:284–92. doi: 10.1002/(sici)1097-0215(19990621)84:3<284::aid-ijc15>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  • 113.Nanda KD, Ranganathan K, Devi U, Joshua E. Increased expression of CK8 and CK18 in leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma: An immunohistochemistry study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:245–53. doi: 10.1016/j.tripleo.2011.05.034. [DOI] [PubMed] [Google Scholar]
  • 114.Sharada S, Milind V, Devendra C, Prakash G, Archana S, Siddheshwar R, et al. Clinicopathological features and prognostic implications of loss of K5 and gain of K1, K8 and K18 in oral potentially malignant lesions and squamous cell carcinomas: An immunohistochemical analysis. Edorium J Tumor Biol. 2014;1:1–22. [Google Scholar]
  • 115.Lerman MA, Almazrooa S, Lindeman N, Hall D, Villa A, Woo SB, et al. HPV-16 in a distinct subset of oral epithelial dysplasia. Mod Pathol. 2017;30:1646–54. doi: 10.1038/modpathol.2017.71. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Oral and Maxillofacial Pathology : JOMFP are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES